Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing -- Ignore unavailable to you. Want to Upgrade?

To: GeoDude who wrote (13882)	1/3/2000 8:56:00 AM
From: GeoDude	Respond to of 118717

And here is the AKRN news release that has all the meat(it is old but the stock has not understood its impact YET): KNOXVILLE, Tenn., Nov. 9 /PRNewswire/ -- Photogen Technologies Inc. (OTC Bulletin Board: PHGN - news) today announced that Akorn Inc. (Nasdaq: AKRN - news), a diagnostic and therapeutic pharmaceutical manufacturer and marketer, will develop certain formulations of the photoactive compound PH-10. PH-10 is a light-sensitive drug that, when activated with X-rays, green light or ultra fast-pulsed near-infrared light, has the potential to treat cancer and certain dermatological conditions virtually anywhere in or on the body. Lung, breast and prostate cancer, Barrett's esophagus and psoriasis are among treatments expected to benefit from the drug. ``Our recent findings, showing a 90 percent 'kill' rate of cancerous tumor cells in laboratory mice within 48 hours of treatment, make PH-10 a potentially groundbreaking drug for oncology and dermatology markets,' said John Smolik, Photogen president and CEO. ``Working with Akorn to advance the drug from the experimental stage to being ready for FDA submissions and then the market is an exciting next step for us.' Illinois-based Akorn will also provide Photogen with necessary background information for meeting regulatory requirements for the Food and Drug Administration (FDA) approval of PH-10. Akorn will develop and document raw materials, production and testing procedures and specifications, necessary for Photogen to use in its new drug applications (NDAs) -- enabling Photogen to leverage Akorn's existing expertise to advance toward FDA approval. ``We are pleased to provide our manufacturing and compliance-related expertise,' said Floyd Benjamin, president and CEO of Akorn, Inc. ``We are eager to help expedite the process of preparing such a significant drug for delivery to market.' Akorn will develop various drug formulations of PH-10 to treat indications in the following markets: -- Deep tissue oncology, such as lung, breast and prostate cancer, for use with X-rays -- Internal body surfaces, such as Barrett's esophagus, for use with green light -- Dermatology, such as psoriasis, for use with green light LIA